secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K
Filed at:   2024-08-27T23:59:59+00:00
Accession:  0000950170-24-100790
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renalytix gets Nasdaq extension to Oct 25, 2024; transfers to Capital Market
----------------------------------------------------------------------------

- Nasdaq Hearings Panel grants until October 25, 2024 to regain compliance with minimum bid price of $1.00.
- ADSs transfer from Nasdaq Global Market to Nasdaq Capital Market effective August 27, 2024.
- Must also achieve $2.5M minimum stockholders' equity and provide 12-month income projections.
- Unaudited cash position $4.7M as of June 30, 2024; cash runway into Q4 2024.
- Advanced discussions with stakeholders for funding and refreshed business plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024100790/0000950170-24-100790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024100790/rnlx-20240823.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-100790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer